Leica Biosystems, Germany, with US headquarters in Richmond, Ill, has acquired Kreatech Diagnostics, Durham, NC, a privately-held provider of DNA fluorescent in-situ hybridization (FISH) probes and target labeling reagents for microarrays.
“This will allow Leica Biosystems to better serve our cytogenetics and anatomic pathology customers,” says Matthias G. Weber, MD, president, Leica Biosystems. “It will also enable us to actively support the future development of personalized medicine by research and drug development companies.
“By standardizing and supporting the interpretation of results with our Aperio ePathology imaging solutions, we will provide our customers with the ability to effectively and efficiently manage ever more complex diagnostic requirements,” Weber adds.
Kreatech will join Leica Biosystems’ Advanced Staining Business Unit based in Newcastle-upon-Tyne, UK. The combined business will develop targeted biomarker menus for Leica’s instrument platforms. L
[Source: Leica Biosystems]
